S&P 500   4,977.40 (-0.67%)
DOW   37,962.62 (+0.50%)
QQQ   418.07 (-1.26%)
AAPL   165.21 (-1.10%)
MSFT   401.21 (-0.76%)
META   486.91 (-2.97%)
GOOGL   154.59 (-0.91%)
AMZN   175.51 (-2.07%)
TSLA   148.94 (-0.66%)
NVDA   804.39 (-5.00%)
AMD   149.63 (-3.51%)
NIO   3.84 (-4.00%)
BABA   68.98 (+0.15%)
T   16.42 (+0.55%)
F   12.14 (+0.66%)
MU   107.35 (-4.09%)
GE   149.95 (-1.96%)
CGC   8.16 (+4.21%)
DIS   112.41 (-0.02%)
AMC   3.25 (+11.30%)
PFE   25.85 (+1.81%)
PYPL   62.32 (+0.35%)
XOM   120.12 (+1.35%)
S&P 500   4,977.40 (-0.67%)
DOW   37,962.62 (+0.50%)
QQQ   418.07 (-1.26%)
AAPL   165.21 (-1.10%)
MSFT   401.21 (-0.76%)
META   486.91 (-2.97%)
GOOGL   154.59 (-0.91%)
AMZN   175.51 (-2.07%)
TSLA   148.94 (-0.66%)
NVDA   804.39 (-5.00%)
AMD   149.63 (-3.51%)
NIO   3.84 (-4.00%)
BABA   68.98 (+0.15%)
T   16.42 (+0.55%)
F   12.14 (+0.66%)
MU   107.35 (-4.09%)
GE   149.95 (-1.96%)
CGC   8.16 (+4.21%)
DIS   112.41 (-0.02%)
AMC   3.25 (+11.30%)
PFE   25.85 (+1.81%)
PYPL   62.32 (+0.35%)
XOM   120.12 (+1.35%)
S&P 500   4,977.40 (-0.67%)
DOW   37,962.62 (+0.50%)
QQQ   418.07 (-1.26%)
AAPL   165.21 (-1.10%)
MSFT   401.21 (-0.76%)
META   486.91 (-2.97%)
GOOGL   154.59 (-0.91%)
AMZN   175.51 (-2.07%)
TSLA   148.94 (-0.66%)
NVDA   804.39 (-5.00%)
AMD   149.63 (-3.51%)
NIO   3.84 (-4.00%)
BABA   68.98 (+0.15%)
T   16.42 (+0.55%)
F   12.14 (+0.66%)
MU   107.35 (-4.09%)
GE   149.95 (-1.96%)
CGC   8.16 (+4.21%)
DIS   112.41 (-0.02%)
AMC   3.25 (+11.30%)
PFE   25.85 (+1.81%)
PYPL   62.32 (+0.35%)
XOM   120.12 (+1.35%)
S&P 500   4,977.40 (-0.67%)
DOW   37,962.62 (+0.50%)
QQQ   418.07 (-1.26%)
AAPL   165.21 (-1.10%)
MSFT   401.21 (-0.76%)
META   486.91 (-2.97%)
GOOGL   154.59 (-0.91%)
AMZN   175.51 (-2.07%)
TSLA   148.94 (-0.66%)
NVDA   804.39 (-5.00%)
AMD   149.63 (-3.51%)
NIO   3.84 (-4.00%)
BABA   68.98 (+0.15%)
T   16.42 (+0.55%)
F   12.14 (+0.66%)
MU   107.35 (-4.09%)
GE   149.95 (-1.96%)
CGC   8.16 (+4.21%)
DIS   112.41 (-0.02%)
AMC   3.25 (+11.30%)
PFE   25.85 (+1.81%)
PYPL   62.32 (+0.35%)
XOM   120.12 (+1.35%)
ASX:RMD

ResMed (RMD) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.23 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
1.02%
Price Target
N/A
RMD stock logo

About ResMed Stock (ASX:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
ResMed share price target raised by RBC Capital
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Expert Outlook: ResMed Through The Eyes Of 9 Analysts
ResMed Inc. (RMD.AX)
RMD Mar 2024 210.000 put
Here's why ResMed shares can jump a further 20%
RMD Mar 2024 220.000 call
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Oppenheimer Keeps Their Buy Rating on Resmed (RMD)
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/13 Dividend
2/06/2024
Dividend Payable
3/13/2024
Today
4/19/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Instruments & Supplies
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
10,140
Year Founded
N/A

Profitability

Net Income
$890.39 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.50 billion
Book Value
A$30.47 per share

Miscellaneous

Outstanding Shares
1,470,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
0.67
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Michael J. Farrell BE (Age 52)
    MBA, SM, CEO & Chairman
    Comp: $4.37M
  • Dr. Peter C. Farrell A.M. (Age 82)
    B.E., BE (Hons), Ph.D., ScD, Founder, Chair Emeritus & Director
    Comp: $654.85k
  • Mr. Brett A. Sandercock (Age 57)
    Chief Financial Officer
    Comp: $1.38M
  • Mr. Robert A. Douglas (Age 64)
    Special Advisor
    Comp: $2.91M
  • Mr. Kaushik Ghoshal (Age 55)
    Chief Commercial Officer - SaaS
    Comp: $1.69M
  • Ms. Amy Wakeham
    Chief Investor Relations Officer
  • Mr. Michael J. Rider (Age 66)
    Chief Legal Officer
  • Mr. Jim Ellis
    Chief Compliance Officer
  • Ms. Yvonne-Katrin Pucknat
    Chief Marketing Officer
  • Ms. Vered Keisar
    Chief People Officer

RMD Stock Analysis - Frequently Asked Questions

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a Interim dividend on Thursday, February 1st. Investors of record on Wednesday, March 13th will be given a dividend of 0.051 per share on Wednesday, March 13th. This represents a yield of 0.18%. The ex-dividend date of this dividend is Tuesday, February 6th.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (ASX:RMD) pays an annual dividend of A$0.29 per share and currently has a dividend yield of 1.02%. The dividend payout ratio is 31.52%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for RMD.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include CSL (CSL), Altium (ALU), Appen (APX), Abbott Laboratories (ABT), Cochlear (COH), FuelCell Energy (FCEL), Flight Centre Travel Group (FLT), Primary Health Care (PRY), Western New England Bancorp (WNEB) and AbbVie (ABBV).

This page (ASX:RMD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners